ABLE Financial Group LLC Acquires Shares of 4,090 Insulet Co. (NASDAQ:PODD)

ABLE Financial Group LLC purchased a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 4,090 shares of the medical instruments supplier's stock, valued at approximately $952,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. lifted its stake in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 58 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Insulet during the 2nd quarter worth about $32,000. UMB Bank n.a. increased its stake in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock worth $37,000 after purchasing an additional 81 shares during the period. CVA Family Office LLC lifted its holdings in shares of Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock worth $50,000 after buying an additional 145 shares during the period. Finally, Massmutual Trust Co. FSB ADV raised its stake in Insulet by 159.2% in the second quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier's stock worth $51,000 after buying an additional 156 shares in the last quarter.

Insulet Stock Performance

NASDAQ:PODD traded up $23.02 during mid-day trading on Friday, hitting $268.00. 1,582,910 shares of the company traded hands, compared to its average volume of 782,076. The firm has a market cap of $18.79 billion, a price-to-earnings ratio of 49.39, a price-to-earnings-growth ratio of 4.47 and a beta of 1.22. Insulet Co. has a one year low of $151.56 and a one year high of $275.52. The stock's fifty day moving average price is $230.70 and its 200-day moving average price is $203.24. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.56 by ($0.01). The business had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. Insulet's revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.38 earnings per share. Research analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Sanford C. Bernstein started coverage on Insulet in a research note on Wednesday. They issued an "outperform" rating and a $300.00 price objective for the company. Barclays boosted their price target on shares of Insulet from $200.00 to $220.00 and gave the company an "equal weight" rating in a research note on Monday, August 12th. Canaccord Genuity Group raised their target price on shares of Insulet from $236.00 to $269.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. UBS Group increased their price objective on Insulet from $211.00 to $223.00 and gave the company a "neutral" rating in a report on Friday, August 9th. Finally, Citigroup upped their price objective on Insulet from $250.00 to $275.00 and gave the stock a "buy" rating in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $246.80.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.